Murae Organisor Past Earnings Performance
Past criteria checks 0/6
Murae Organisor has been growing earnings at an average annual rate of 2.6%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 38.8% per year.
Key information
2.6%
Earnings growth rate
-6.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -38.8% |
| Return on equity | -1.7% |
| Net Margin | -22.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Murae Organisor makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 41 | -9 | 4 | 0 |
| 30 Sep 23 | 48 | 4 | 4 | 0 |
| 30 Jun 23 | 115 | 13 | 1 | 0 |
| 31 Mar 23 | 141 | 20 | 4 | 0 |
| 31 Dec 22 | 173 | 11 | 1 | 0 |
| 30 Sep 22 | 210 | 6 | 0 | 0 |
| 30 Jun 22 | 223 | 63 | 0 | 0 |
| 31 Mar 22 | 210 | 22 | 0 | 0 |
| 31 Dec 21 | 158 | 49 | 3 | 0 |
| 30 Sep 21 | 136 | 37 | 4 | 0 |
| 30 Jun 21 | 246 | -28 | 5 | 0 |
| 31 Mar 21 | 411 | 1 | 5 | 0 |
| 31 Dec 20 | 552 | -14 | 4 | 0 |
| 30 Sep 20 | 660 | -7 | 4 | 0 |
| 30 Jun 20 | 606 | 6 | 4 | 0 |
| 31 Mar 20 | 551 | 18 | 4 | 0 |
| 31 Dec 19 | 577 | 21 | 3 | 0 |
| 30 Sep 19 | 569 | 11 | 4 | 0 |
| 30 Jun 19 | 538 | 14 | 5 | 0 |
| 31 Mar 19 | 507 | 17 | 5 | 0 |
| 31 Mar 18 | 354 | 9 | 3 | 0 |
| 31 Mar 17 | 233 | 2 | 3 | 0 |
| 31 Mar 16 | 186 | 1 | 5 | 0 |
Quality Earnings: 542724 is currently unprofitable.
Growing Profit Margin: 542724 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 542724 is unprofitable, but has reduced losses over the past 5 years at a rate of 2.6% per year.
Accelerating Growth: Unable to compare 542724's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 542724 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 542724 has a negative Return on Equity (-1.65%), as it is currently unprofitable.